The French Speciality Pharmaceutical Company, Juvisé Pharmaceuticals Acquires Two Oncology Products From AstraZeneca in Over 40 Countries
The French speciality pharmaceutical company, Juvisé Pharmaceuticals is pleased to announce the successful completion of a transaction with AstraZeneca, regarding the acquisition of the commercial rights of Arimidex® (anastrozole ) and Casodex® (bicalutamide ) in a number of European, African and other countries.
This first transaction of Juvisé Pharmaceuticals with AstraZeneca is a logical next step after multiple worldwide deals accomplished by the French company with several other big pharmaceutical companies over the past years.
With this acquisition, Juvisé Pharmaceuticals enters the oncology therapeutic area, in which the company wants to further expand and consolidates its fast-growing ambition.
Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared “we are very pleased to have successfully closed our first deal with AstraZeneca and to enter a therapeutic area with high medical needs such as oncology with Arimidex® and Casodex®, which are two widely recognized cancer treatments essential for both patients and physicians”.
Arimidex® (anastrozole ) is an aromatase inhibitor, indicated primarily for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and the treatment of advanced breast cancer in postmenopausal women with disease progression, following tamoxifen therapy.
Casodex® (bicalutamide ) is an androgen-receptor inhibitor, indicated for use in combination therapy with a luteinising hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.
About Juvisé Pharmaceuticals
Juvisé Pharmaceuticals is an international pharmaceutical company, specialized in manufacturing and commercializing ethical original drugs with high medical value for patients suffering from cardiovascular, oncology or neuro-psychiatric diseases.
11 years after its creation, Juvisé Pharmaceuticals has become a recognized international company commercializing its own drugs in 75 countries around the word.
For more information, please visit juvisepharmaceuticals.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-ANDERSEN-GLOBAL12.8.2020 15:56:09 CEST | Pressemeddelelse
Andersen Global styrker platformen i Afrika med tilføjelsen af et advokatfirma i Gabon
BOEHRINGER-INGELHEIM12.8.2020 14:38:12 CEST | Press release
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
CA-VELODYNE-LIDAR,-INC.12.8.2020 14:02:09 CEST | Press release
Velodyne Lidar Powering Intelligent Traffic Management in Nevada
NY-MOODY’S-ANALYTICS12.8.2020 13:32:10 CEST | Press release
Moody’s Analytics Three-Peats in Two Categories at Risk Technology Awards
MN-IMRICOR-MEDICAL12.8.2020 13:02:08 CEST | Press release
Imricor Announces Sales Collaboration with Optoacoustics
SAMSUNG-DISPLAY12.8.2020 10:21:10 CEST | Press release
Samsung Display Commercializes New, Variable Refresh Rate Technology for Increasing Smartphone Power Savings
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom